Business Context and Reporting Period
Company: Immunocore Holdings Plc
Filing Type: Form 8-K (Current Report)
Date of Report: March 10, 2025
Event: Regulation FD Disclosure regarding clinical trial data presentation.
Key Financial Metrics
This filing is a current report regarding a clinical trial update and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
There are no financial material changes reported in this document. The material event is the presentation of initial data from the multiple ascending dose (MAD) portion of the Phase 1/2 STRIVE trial for the investigational product IMC-M113V.
Outlook, Management Commentary, and Risks
- Clinical Data Presentation: The Company presented data at the Conference on Retroviruses and Opportunistic Infections (CROI) 2025 in San Francisco.
- Trial Status: Data covers the completion of the third cohort of the STRIVE trial in people living with human immunodeficiency virus (HIV).
- Key Findings:
- IMC-M113V was observed to be well tolerated.
- Signals of dose-dependent reduction in active reservoir were observed.
- Signals of viral control were observed after antiretroviral treatment was interrupted.
- Investor Relations: An investor presentation summarizing this data was made available on the Company's website for use in analyst and investor meetings.
Important Facts for Investor Verification
- Verify the full details of the STRIVE trial data in the attached Press Release (Exhibit 99.1) and the investor presentation on the Company website.
- Confirm the specific statistical significance and sample size of the "signals" regarding viral control and reservoir reduction mentioned in the summary.
- Note that the information in Item 7.01 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting liability exposure for the Company regarding these statements.
- Check subsequent filings for any updates on the trial's progression beyond the third cohort.